Recent Updates
Recently added Catalysts

Prucalopride

Phase 3

Male Subjects With Chronic Constipation | Small molecule | Gastrointestinal |Takeda Pharmaceutical Company Limited|Last Updated: Jun 10, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment374
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01147926Evaluation of Prucalopride in Male Subjects With Chronic Constipation.PHASE3 COMPLETED 374Sep 23, 2010Oct 25, 2013Jun 10, 202173 Belgium, Bulgaria +8
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week
Over 12 week treatment period

Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.

Secondary Endpoints
Percentage of Subjects With an Average Weekly Frequency of at Least 3 SCBM Per Week and an Increase of ≥ 1 SCBM Per Week for ≥ 75% of the 12-week Treatment Period and ≥ 75% of the Last Third of the 12-week Treatment Period
Over 12 week treatment period
Percentage of Subjects With an Increase of at Least 1 SCBM Per Week
Over 12 week treatment period
SCBM Per Week
Over 12 week treatment period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PlaceboPLACEBO_COMPARATORPlacebo
PrucaloprideACTIVE_COMPARATOR1 milligram (mg) or 2 mg
Interventions
NameTypeDescription
PlaceboDRUGPlacebo matched to Prucalopride tablet orally once daily.
PrucaloprideDRUGPrucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (\<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexMALE
Healthy VolunteersNo
Study Sites73

Inclusion Criteria: 1. Subject is a male out-patient ≥18 years of age (no upper age limit). 2. Subject has a history of constipation. The subject reports an average of ≤ 2 SBM/week that result in a feeling of complete evacuation (SCBM) and one or more of the following for at least 6 months before t...

Countries:BelgiumBulgariaCzechiaDenmarkFranceGermanyNetherlandsPolandRomaniaUnited Kingdom
Unlock Eligibility Criteria